X
Celcuity
  • Our approach
    • Our Approach
    • Publications
  • Our Pipeline
    • Our Pipeline
    • PI3K/AKT/mTOR (PAM) Pathway
    • Gedatolisib
    • Expanded Access Program
  • Clinical Trials
    • VIKTORIA-1: Breast Cancer
    • VIKTORIA-2: Breast Cancer
    • CELC-G-201: Prostate Cancer
  • About
    • About
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
    • IR Alerts
  • Careers
    • Overview
    • Culture & benefits
    • Hiring, development & advancement
    • Open Positions
  • News
  • Contact
Celcuity
  • News
  • Contact
  • Our approach
    • Our Approach
    • Publications
  • Our Pipeline
    • Our Pipeline
    • PI3K/AKT/mTOR (PAM) Pathway
    • Gedatolisib
    • Expanded Access Program
  • Clinical Trials
    • VIKTORIA-1: Breast Cancer
    • VIKTORIA-2: Breast Cancer
    • CELC-G-201: Prostate Cancer
  • About
    • About
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
    • IR Alerts
  • Careers
    • Overview
    • Culture & benefits
    • Hiring, development & advancement
    • Open Positions
Celcuity
© Celcuity, Inc.
16305 36th Avenue North
Minneapolis, MN 55446

Quick Links

  • About
  • Contact
  • Privacy Policy
  • Accessibility Statement

Follow us on